As of February 11, 2026, a prospective exploratory study is listed on ClinicalTrials.gov to assess the comprehensive application effectiveness of exercise prescription decision support tools in the management of patients with four highs Hypertension, Hyperglycemia, Hyperlipidemia and Hyperuricemia. The study describes a digital intervention described as a behavioral program using an enhanced mini program along with an enhanced control arm. The sponsor is the China National Center for Cardiovascular Diseases. This listing highlights ongoing efforts to test digital health tools that aim to support lifestyle based cardiovascular and metabolic risk management. Regulators and stakeholders should monitor how the listing defines intended use, what performance is proposed and how safety will be tracked as recruitment progresses.
What changed in the listing and why regulators should care
The listing shows two behavioral elements tied to a digital intervention: Enhanced Mini Program Intervention and Enhanced Control. The phrase mini program refers to software that guides exercise related decisions. The combination points to an evaluation of a digital decision support approach for exercise prescription in a patient group with four linked conditions. Regulators will want to see clear definitions of intended use, the basis for any safety assumptions and how outcomes will be measured in this exploratory setting. The sponsor China National Center for Cardiovascular Diseases is listed as the sponsor, indicating oversight from a national cardiovascular health institution.
What is the focus of the prospective exploratory study on four highs and exercise prescription decision tools?
At its core the study seeks to test whether exercise prescription decision support tools can improve management of patients with the four highs. The conditions listed are Hypertension, Hyperglycemia, Hyperlipidemia and Hyperuricemia. The design uses a digital intervention and two behavioral arms to test supplementary and control approaches. The aim is to gather evidence on applicability across a complex risk profile rather than to generate immediate practice level efficacy statements.
What interventions are described and what outcomes are anticipated?
The listed interventions are behavioral: Enhanced Mini Program Intervention and Enhanced Control. The mini program is a digital tool that supports exercise prescriptions and related guidance. The enhanced implies an iterative improvement of a software driven approach. The control arm is described as enhanced as well, indicating an active comparator design. No numerical outcomes are provided in the listing; the trial is described as exploratory and focused on application effectiveness rather than a final decision on use. Regulators will look for defined endpoints and data collection methods to assess how the tool performs in real world settings.
What are the regulatory implications?
Because the intervention is described as a digital intervention that supports exercise prescription, questions arise about its intended use and performance claims in a regulatory context. Without explicit device claims the tool may be viewed as a digital health solution that requires appropriate privacy and data handling. If future results suggest a device like performance claims, the tool may need regulatory review under medical device rules in relevant jurisdictions including MDR Annex XIV. The listing also shows the sponsor and the site, which may indicate oversight by national regulators in China and possible international registration depending on the jurisdiction.
What happens next?
Recruitment is indicated in the listing. No trial results are provided yet. Regulators will watch for updates in the ClinicalTrials.gov entry and for any published results or safety data as the trial proceeds. The presence of the external link enables readers to verify current status and details.
FAQ
- Q1 What is the Four Highs concept in this listing?
Answer The Four Highs refer to hypertension, hyperglycemia, hyperlipidemia and hyperuricemia. The trial aims to evaluate a digital intervention for exercise prescription in people with these conditions. - Q2 What is the intervention described?
Answer The interventions are behavioral Enhanced Mini Program Intervention and Enhanced Control. The first uses a digital mini program to guide exercise prescription and the second serves as an enhanced comparator. - Q3 Who is sponsoring?
Answer The sponsor listed is the China National Center for Cardiovascular Diseases. - Q4 Where can I get more information?
Answer The ClinicalTrials.gov listing at https://clinicaltrials.gov/study/NCT07400549?term=medical+device provides current status and details.
In summary this listing reflects ongoing testing of digital decision support tools for exercise prescription in a multi condition population. For regulators and industry stakeholders the key takeaways are to await clear definitions of use, safety and performance and to monitor how recruitment unfolds as the study progresses.
This information is intended for professionals and is not legal advice. It is provided for informational purposes only and should not be treated as regulatory counsel or a substitute for legal guidance.
https://clinicaltrials.gov/study/NCT07400549?term=medical+device